EMA advises on how to prevent medication errors with new forms and indications
This article was originally published in SRA
In yet another move prompted by the new EU pharmacovigilance legislation, companies proposing to market products similar to ones already on the market are being asked to take extra steps to prevent potential medication errors, particularly involving substances that have a narrow therapeutic index1.
You may also be interested in...
The Australian government is investing in two candidate vaccines being developed in Melbourne, French firm Avaxia is looking at the virucidal potential of an antibacterial compound, and Canada has ordered millions of specialist vials and syringes from an advanced materials science firm based in Alabama.
As the final scheduled round of post-Brexit trade talks begins amid growing concern over the prospect of a deal and the pervasive threat of COVID-19, the pharmaceutical industry in the UK and the EU have issued an urgent call for an MRA on medicines GMP. They also want to see a one-year phase-in of medicines-related aspects of the Northern Ireland Protocol.
With coronavirus cases again on the rise in many European countries, members of two EU parliamentary committees asked industry representatives to explain why details of COVID-19 vaccine supply agreements are being kept under wraps.